Exosens
RODEN, NETHERLANDS / ACCESSWIRE / April 9, 2024 / Exosens is pleased to announce a partnership with Photonscore, a provider of instrumentation for time-correlated single photon imaging. Through this partnership, Exosens will distribute LINCam, an innovative camera system with picosecond time resolution through their Photonis-branded scientific imaging product portfolio.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page."We are delighted to partner with Photonscore and add LINCam to our scientific imaging solutions to our potential customers. LINCam is a breakthrough technology that enables fast and accurate time-resolved imaging for a variety of applications, such as biomedical research, material science, and quantum optics. LINCam complements our existing product line and combined will provide a unique value proposition." - Ulrich Laupper, President and Executive General Manager of the Exosens Ultimate Detection Business Unit.
LINCam is an easy-to-use, event-based camera that counts photons at high rate with the picosecond time resolution combined with accurate position information. Paired with a pulsed light source, LINCam can turn any conventional microscope into a powerful lifetime imager.
The partnership between Exosens and Photonscore is supported by Photonis, a brand of Exosens, which provides a crucial component of the camera: the high-time resolution position-sensitive MCP-PMT detector. Photonis has optimized the MCP-PMT which allows for the best properties for LINCam performance by providing high quantum efficiency and low dark rate photocathodes in a broad spectral range and also by implementing high linearity and high gain MCPs to increase the dynamic operational range. As a result of Exosens and Photonscore's close technical collaboration, the state-of-the-art high-time resolution single-photon camera LINCam becomes the optimal solution for widefield microscopy and other highly demanding applications.
"At Photonscore we are excited to start a productive partnership with Exosens. Their knowledge and experience in the field of photon detection gave us a big leap in the quality and capability of our system. In particular, the outstanding technology of Hi-QE photocathodes and high-performance MCPs enables us to bring LINCam to the applications where we did not dare enter into before." - Yury Prokazov, CEO, Photonscore GmbH
ABOUT PHOTONSCORE:
Photonscore GmbH specializes in simplifying single photon counting for its customers. The company's primary product, the LINCam, is a single photon counting camera with a 100% fill-factor and minimal noise. The company is serving leading universities and research institutes across the world, reflecting the broad applicability of its technologies. Photonscore's contributions to the field have been recognized with several awards. These include the 1st Prize in the Hugo-Junkers-Award 2017 for innovative applied research and nomination as a finalist in the German Innovation Award 2019. Photonscore is committed to advancing photon counting technology, striving to make it more accessible and effective for a wide range of applications.
ABOUT PHOTONIS:
Photonis is a leading brand of Exosens, a high-tech company with more than 85 years of experience in the innovation, development, manufacture, and sale of high-end electro-optical technologies used in the detection of ions, electrons, and photons. The Photonis brand portfolio offers photo-detection and low-light conditions imaging solutions for extremely demanding markets such as Defense & Security, Nuclear Safety, Life Science, and Industrial & Non-Destructive testing. Photonis is internationally recognized as a leading brand and a major innovator in its fields with production and R&D sites in Europe and North America.
For more information: exosens.com
Contact: scientificdetectors@exosens.com
Contact Information
Sales Manager
scientificdetectors@exosens.com
+31 50 501 8808
SOURCE: Photonis
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Advances Community-Led Forest Protection in Colombia's Meta Region19.11.2025 15:00:00 CET | Press release
New phase of the Sur del Meta Project expands carbon and biodiversity monitoring while strengthening local governance and livelihoods. CALGARY, AB / ACCESS Newswire / November 19, 2025 / In the heart of Colombia's Meta department, where forests and farmlands converge, Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is deepening its commitment to people-powered climate solutions through the REDD+ Sur del Meta Project - a long-term conservation initiative that protects 40,637 hectares of natural forest while supporting sustainable livelihoods for nearly 1,000 local families. Developed through ALLCOT - A Karbon-X Company, the project development and advisory arm of Karbon-X, the initiative operates across the municipalities of Vistahermosa, Puerto Rico, Puerto Concordia, and Puerto Lleras, a region historically affected by deforestation and armed conflict. The project partners with local farmers, many of whom are victims of Colombia's armed conflict, helping them transition from
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom